Switch theme
Sign up to access all valuation multiples
Celon Pharma SA is a Poland based company engages in the research of therapeutic solutions and development, production, distribution, and marketing of specialized generic products. It invests in the development of innovative pharmaceuticals with potential applications in the treatment of cancer, neurological diseases, diabetes and other metabolic disorders. Its products portfolio comprises pills, such as Aromek, Bosentan Celon, Donepex, Ketrel, Lazivir, and Valzek, as well as inhalation powder.
2002
297
LTM Revenue $75.7M
LTM EBITDA $19.9M
$306M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Celon Pharma has a last 12-month revenue (LTM) of $75.7M and a last 12-month EBITDA of $19.9M.
In the most recent fiscal year, Celon Pharma achieved revenue of $43.6M and an EBITDA of $8.7M.
Celon Pharma expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Celon Pharma valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $75.7M | XXX | $43.6M | XXX | XXX | XXX |
| Gross Profit | $75.7M | XXX | $25.9M | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | 59% | XXX | XXX | XXX |
| EBITDA | $19.9M | XXX | $8.7M | XXX | XXX | XXX |
| EBITDA Margin | 26% | XXX | 20% | XXX | XXX | XXX |
| EBIT | $6.6M | XXX | -$8.2M | XXX | XXX | XXX |
| EBIT Margin | 9% | XXX | -19% | XXX | XXX | XXX |
| Net Profit | $7.0M | XXX | -$7.5M | XXX | XXX | XXX |
| Net Margin | 9% | XXX | -17% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Celon Pharma's stock price is PLN 22 (or $6).
Celon Pharma has current market cap of PLN 1.2B (or $314M), and EV of PLN 1.2B (or $306M).
See Celon Pharma trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $306M | $314M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Celon Pharma has market cap of $314M and EV of $306M.
Celon Pharma's trades at 7.0x EV/Revenue multiple, and 35.2x EV/EBITDA.
Equity research analysts estimate Celon Pharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Celon Pharma has a P/E ratio of 44.7x.
See valuation multiples for Celon Pharma and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $314M | XXX | $314M | XXX | XXX | XXX |
| EV (current) | $306M | XXX | $306M | XXX | XXX | XXX |
| EV/Revenue | 4.0x | XXX | 7.0x | XXX | XXX | XXX |
| EV/EBITDA | 15.3x | XXX | 35.2x | XXX | XXX | XXX |
| EV/EBIT | 46.1x | XXX | -37.2x | XXX | XXX | XXX |
| EV/Gross Profit | 4.0x | XXX | n/a | XXX | XXX | XXX |
| P/E | 44.7x | XXX | -42.1x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -28.0x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialCelon Pharma's last 12 month revenue growth is -2%
Celon Pharma's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.1M for the same period.
Celon Pharma's rule of 40 is 4% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Celon Pharma's rule of X is 21% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Celon Pharma and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | -2% | XXX | 30% | XXX | XXX | XXX |
| EBITDA Margin | 26% | XXX | 20% | XXX | XXX | XXX |
| EBITDA Growth | -21% | XXX | 176% | XXX | XXX | XXX |
| Rule of 40 | 4% | XXX | 18% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 21% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 78% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Celon Pharma acquired XXX companies to date.
Last acquisition by Celon Pharma was XXXXXXXX, XXXXX XXXXX XXXXXX . Celon Pharma acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Celon Pharma founded? | Celon Pharma was founded in 2002. |
| Where is Celon Pharma headquartered? | Celon Pharma is headquartered in Poland. |
| How many employees does Celon Pharma have? | As of today, Celon Pharma has 297 employees. |
| Is Celon Pharma publicy listed? | Yes, Celon Pharma is a public company listed on WAR. |
| What is the stock symbol of Celon Pharma? | Celon Pharma trades under CLN ticker. |
| When did Celon Pharma go public? | Celon Pharma went public in 2017. |
| Who are competitors of Celon Pharma? | Similar companies to Celon Pharma include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Celon Pharma? | Celon Pharma's current market cap is $314M |
| What is the current revenue of Celon Pharma? | Celon Pharma's last 12 months revenue is $75.7M. |
| What is the current revenue growth of Celon Pharma? | Celon Pharma revenue growth (NTM/LTM) is -2%. |
| What is the current EV/Revenue multiple of Celon Pharma? | Current revenue multiple of Celon Pharma is 4.0x. |
| Is Celon Pharma profitable? | Yes, Celon Pharma is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Celon Pharma? | Celon Pharma's last 12 months EBITDA is $19.9M. |
| What is Celon Pharma's EBITDA margin? | Celon Pharma's last 12 months EBITDA margin is 26%. |
| What is the current EV/EBITDA multiple of Celon Pharma? | Current EBITDA multiple of Celon Pharma is 15.3x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
